Regenerex Pharma enters exclusive collagen supply deal with Holista; minimum purchases ramp to $9M/yr

REGENEREX PHARMA, INC.

Exclusive worldwide rights to Holista's ovine collagen for wound care; initial focus on U.S. market.
Minimum purchase commitments: $50k in 2025, $3M in 2026, $6M in 2027, $9M annually from 2028.
Regenerex to fund clinical studies and FDA regulatory approvals for advanced wound care products.
Joint collaboration on nano-collagen applications with shared IP ownership.
Agreement runs for life of patents; can be terminated on 90 days' notice or for breach/insolvency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.